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Objectives This study aimed to appraise 2-year outcomes after percutaneous treatment of femo-
ropopliteal artery disease with paclitaxel-eluting balloons.
Background Percutaneous transluminal angioplasty with paclitaxel-eluting balloons for femoropop-
liteal artery disease has provided favorable 1-year results.
Methods Consecutive patients with Rutherford class 2 to 4 disease due to femoropopliteal lesions
15 mm long and with 3- to 7-mm reference vessel diameter were prospectively enrolled in a mul-
ticenter registry. Endpoints of interest included primary patency, major adverse events (the compos-
ite of death, amputation, or target lesion revascularization), changes in Rutherford class, ankle-
brachial index, absolute claudication distance, and quality of life after 24 months.
Results A total of 105 patients (114 lesions) treated with paclitaxel-eluting balloons and provisional
stenting were enrolled, and ﬁnal procedural success was obtained in all. Follow-up after 27  3
onths was obtained in 98 (93.3%) patients, showing that primary patency was maintained in
1 (72.4%), and major adverse events had occurred in 17 (17.5%), with persistently signiﬁcant
eneﬁts in Rutherford class, ankle-brachial index, absolute claudication distance, and quality of life
all p  0.001). Secondary patency rate was achieved in 89 cases (84.7%).
onclusions PEBs are associated with favorable functional and clinical outcomes at 2 years in pa-
ients with femoropopliteal artery disease requiring percutaneous revascularization. (J Am Coll
ardiol Intv 2013;6:282–9) © 2013 by the American College of Cardiology Foundation
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283Ongoing developments in devices and techniques for per-
cutaneous transluminal angioplasty (PTA) have made this
minimally invasive treatment strategy a mainstay in the
management of patients with femoropopliteal artery disease
requiring revascularization, especially when atherosclerotic
burden or surgical risk do not favor bypass surgery (1–3).
See page 290
Among the multiple technological developments, the intro-
duction of paclitaxel-eluting balloons (PEB) holds the
promise of a safe and effective therapy for atherosclerotic
disease in this vascular district, limiting stenting—with its
potential negative consequences, such as stent fracture—to
bail-out indications (4–7). However, all PEB published trials
so far have been based on a 6-month angiographic primary
endpoint, and none have looked at Primary Patency at 1 and 2
years or extended the analysis to functional endpoints. This
holds true for PEB as well as for new devices in general,
because objective lesion specific endpoints such as primary
patency and more meaningful functional outcomes such as
walking capacity and quality of life are not always reported,
thus limiting sound clinical decision-making.
We have previously reported the findings of a prospective
multicenter study, including 105 patients undergoing femo-
ropopliteal PTA with PEB and showing favorable clinical
results up to 12 months (7). With the objective of providing
similarly detailed results on this treatment strategy at
long-term follow-up, we hereby report on the 24-month
outcomes of this patient cohort.
Methods
Design. This was an independent, nonindustry-supported
rospective multicenter study aimed to appraise in detail
atal and nonfatal outcomes after femoropopliteal PTA with
he In.Pact Admiral PEB (Medtronic, Frauenfeld, Switzer-
and) (7). The registry was approved by local ethics com-
ittees, and all patients signed an informed consent form.
Patients. Adult patients diagnosed with peripheral artery
disease for claudication or rest pain as per Rutherford class
2 to 4 were screened. Angiographic inclusion criteria in-
cluded atherosclerotic disease of the superficial femoral
artery, including the first 2 segments of the popliteal artery,
with reference diameter between 3 and 7 mm, having
stenotic lesions or occlusions for a total length150 mm by
visual estimate. Long lesions or multiple adjacent lesions
were cumulatively considered and treated as a single lesion.
Patients were required to have adequate runoff with evi-
dence of at least 1 patent crural vessel to the foot either
pre-existing or re-established (patients were eligible if an
impaired outflow vessel [50% diameter stenosis] was
treated during the index procedure). Unhindered inflow in
the aortic-iliac and common femoral districts (either pre-existing or re-established) was also required for patient
inclusion. Long (150 mm) inflow lesions constituted an
exclusion criterion, whereas patients presenting with shorter
lesions were deemed eligible if these inflow lesions could be
successfully treated before the target femoropopliteal lesion.
In-stent restenosis, aneurysm in the target vessel, or acute
thrombus in the target limb constituted exclusion criteria.
Other exclusion criteria included failure to cross the target
lesion with a guidewire, and concomitant (intentional or
accidental) use of alternative therapies in the target vessel,
including atherectomy, excimer laser, or cutting balloon
during the index procedure.
Procedures and devices. Patients not taking aspirin and
clopidogrel before study enrollment received loading doses
of 300 mg of aspirin and 300 mg of clopidogrel 12 h before
the procedure. After PTA, all subjects received 100 mg/day
of aspirin indefinitely and 75 mg/day clopidogrel for 12
weeks (6 months in case of stenting). Patients received a
bolus of 5,000 IU of heparin after insertion of the sheath in
the common femoral artery. Vascular access was accom-
plished via the contralateral or ipsilateral approach. After
crossing the lesion with a guide-
wire, pre-dilation (2 min) with
an undersized uncoated balloon
(0.5 to 1 mm smaller) was fol-
lowed by insertion of PEB of
appropriate size and length. The
target lesion was dilated 10 mm
beyond both ends of the lesion
with a PEB with vessel/balloon
ratio of 1:1 (on the basis of visual
estimate) and an inflation time
of 3 min at 6 to 12 atm. Study
balloons were inflated only once. An additional long (at least
3 min) inflation with an adequate (same size or 0.5-mm
larger than PEB) uncoated balloon was performed in the
tract where angiography revealed persistent stenosis 50%
or dissection. If suboptimal results persisted after such
repeated dilation, self-expanding nitinol stents were im-
planted as bail-out, in all cases covering the whole lesion
length.
Deﬁnitions and endpoints. Device success was defined as
successful vascular access and exact deployment of the device
according the instructions for use, whereas technical success
was defined as device success plus completion of the
endovascular procedure, obtaining 30% residual stenosis
of the treated lesion by visual estimate.
Endpoints of interest were primary patency rate, de-
fined as freedom from the combined endpoints of target
lesion revascularization (TLR), occlusion, and 50%
restenosis in the treated lesion as appraised by duplex
ultrasound performed by an independent reader (peak
systolic velocity ratio 2.4); secondary patency, defined
Abbreviations
and Acronyms
ACD  absolute claudication
distance
PEB  paclitaxel-eluting
balloons (s)
PTA  percutaneous
transluminal angioplasty
TLR  target lesion
revascularizationas freedom from 50% restenosis (as previously speci-
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284fied) even if after a re-intervention to restore patency;
major adverse events (the composite of death, amputa-
tion, or TLR); change in Rutherford class; change in
ankle-brachial index; change in walking capacity; change
in absolute claudication distance (ACD); and change in
quality of life parameters (7). Notably, walking capacity
was measured with a validated 5-point walking impair-
ment questionnaire that assessed walking distance, speed,
ability to climb stairs, and symptoms with walking (8).
Absolute claudication distance was defined as the dis-
tance at which the patient could no longer ambulate on
the basis of the 6-min walking test. Quality of life was
assessed with the Euro QoL-5D Questionnaire (9). This
tool looks at 5 dimensions of health: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression.
Each dimension has 3 levels: no problems, some problems, or
extreme problems. Finally, during each follow-up visit, patients
completed a visual analogue scale (0 to 100) to assess their
overall health state. All such endpoints were collected at
baseline and 3, 6, 12, and—for the purpose of the present
study—24 months after the index procedure.
Statistical analysis. Descriptive statistics (frequency and
percentage for categorical variables and mean  SD for
continuous variables) were used to present baseline and
follow-up variables. Additionally, the Kaplan-Meier esti-
mate was used for primary patency. Inferential statistics
were used as follows: Rutherford classification and the
categorical variables of quality of life were compared with
the Kruskal-Wallis test; continuous variables (visual ana-
logue scale, walking impairment questionnaire, ankle-
brachial index, ACD, and peak systolic velocity ratio) were
compared with the Student t test. The EuroQoL-5D levels
were dichotomized into “no problems” and “problems” for
graphical presentation. The data underwent inferential anal-
Table 1. Baseline Patient Characteristics (N105)
Age (yrs) 68 9
Female 20 (19.0%)
Hypertension 90 (85.7%)
Hyperlipidemia 78 (74.3%)
Diabetic status
Nondiabetic 54 (51.4%)
Noninsulin-dependent diabetic 28 (26.7%)
Insulin-dependent diabetic 23 (45.1%)
Current smoking 66 (62.8%)
Renal failure 2 (1.9%)
Coronary artery disease 45 (42.9%
Carotid artery disease 15 (14.3%)
Ankle-brachial index 0.56 0.15
Rutherford class
1 1 (0.9%)
2 28 (26.7%)
3 68 (64.8%)Values are mean SD or n (%).ysis with the Kruskal-Wallis test to determine any statistical
difference between the study visits. Statistical significance
was set at the 2-tailed 0.05 level, and p values unadjusted for
multiplicity are reported throughout. The independent sam-
ple tests instead of pair tests, with all available data, have
been used in the analysis because not all patients showed up
at all follow-up visits.
Results
A total of 105 patients were enrolled, being treated with 135
PEBs in 114 femoropopliteal lesions, which were 76  38
mm long and had a 5.2  0.6 mm reference vessel diameter
and a 92.5  8.2% diameter stenosis, as evaluated by visual
estimation by an independent operator (Tables 1, 2, and 3).
Table 2. Baseline Lesion Characteristics
Patients 105
Lesions 114
Lesion type
De novo 109 (95.6%)
Restenosis 4 (3.5%)
In-stent restenosis 1 (0.9%)
Calciﬁcation
None 38 (33.3%)
Moderate 57 (50.0%)
Severe 19 (16.7%)
Lesion length (mm) 76.3 38.3
Reference vessel diameter (mm) 5.2 0.6
Diameter stenosis (%) 92.5 8.2
Total occlusion 34 (29.8%)
Eligible inﬂow disease 5 (4.8%)
Outﬂow disease (presence of at least 1 nonpatent vessel) 66 (62.9%)
Values are n, n (%), or mean SD.
Table 3. Procedural Details
Patients 105
Lesions 114
Drug-eluting balloon devices 135
Inﬂow lesion successfully treated 5 (100%)
Outﬂow lesions successfully treated 66 (100%)
Lesion crossing
True lumen 105 (92.1%)
Subintimal 9 (7.9%)
Pre-dilation 113 (99.1%)
Post-dilation 20 (17.5%)
Stenting 14 (12.3%)
For ﬂow-limiting dissection 11 (9.6%)
For persistent stenosis 3 (2.6%)
Drug-eluting balloon inﬂation time (s) 181 20
Drug-eluting balloon/lesion ratio 1.18
Residual diameter stenosis (%) 12.2 9.5
Device success 135 (100%)4 8 (7.6%) Technical success 121 (89.6%)Values are n, n (%), or mean SD.
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285Procedural success was obtained in all cases, with bail-out
stenting in 14 (12.3%) lesions.
Further to the primary patency of 83.7% reported at 1
year, clinical follow-up at 27 3 months was obtained in 98
93.3%) patients, showing that primary patency had been
aintained in 71 (72.4%) patients at 2 years (Fig. 1), with
econdary patency rate in 89 cases (84.7%). All TLR at any
ime-point were performed with standard PTA and without
djunctive stenting. The 12- to 27-month primary patency
Figure 2. Two-Year Primary Patency by Lesion Location
Differences in primary patency for lesion located in the superﬁcial femoral
Figure 1. Two-Year Primary Patency
Kaplan-Meier curve representing freedom from target lesion revasculariza-
tion or restenosis 50% (primary patency) at 2 years.(SFA) or popliteal (Popl) arteries (p  NS).among the patients who had not binary restenosis or TLR
at 1 year was 85.1%, and TLR rate was 7.1%, showing no
late catch-up phenomenon. Involvement of popliteal artery
disease determined a decreased albeit nonstatistically signif-
icant primary patency rate (Fig. 2). No statistically signifi-
Figure 3. Two-Year Primary Patency in Stented and Nonstented Lesions
Differences in primary patency for lesions followed by provisional stenting
versus those nonstented (p  NS).
Figure 4. Two-Year Primary Patency in Occluded and Nonoccluded
Lesions
Differences in primary patency for occlusive versus nonocclusive lesions
(p  NS).
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extending 360° circumferentially and at least 3 cm longitudinally (p  NS).
vessel at baseline and reestablishment of 1 vessel patency post-procedure.
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286cant difference in patency rates was noted in stented patients
compared with nonstented (69.2% vs. 75.4%, p  0.426)
Fig. 3), in patients presenting with occlusive versus non-
cclusive stenosis (Fig. 4) and in patients with severe
alcified lesions versus non-severely calcified lesions (Fig. 5).
lso the number of patent crural vessels seems to influence
atency (Fig. 6). As expected, patency rate was significantly
ffected by lesion length: the univariate Cox analysis for
esion length gave a significant hazard ratio of 1.016 (95%
onfidence interval: 1.004 to 1.027, p  0.006).
At 27  3-month follow-up, major adverse events had
occurred in 17 (17.5%), with death in 2 (2.2%), amputation
in 1 (1.0%), and TLR in 14 (14.3%) (Fig. 7). In all cases
TLR was successful. Appraisal of changes in ankle-brachial
index showed persistent improvements up to 27 3 months
(0.88 at such time point versus 0.86 at 12 months, and 0.56
at baseline; p  0.001) (Fig. 8), with similarly favorable
results for ACD (418 m vs. 316 m and 111 m, respectively;
p  0.001) (Fig. 9), Rutherford class (p  0.001) (Fig. 10),
and key quality of life functional measurements (p  0.001
for mobility, usual activities, pain/discomfort) (Fig. 11).
1.1% 1.1%
2.2% 2.2%
0.0% 0.0% 0.0%
1.0%1.1%
4.5%
7.6%
14.3%
2.2%
5.6%
9.8%
17.5%
0.0%
25.0%
3-month 6-month 12-month 27-month
death amputaon TLR composite
Figure 7. Major Adverse Events
Death, amputation, target lesion revascularization (TLR), and composite
event rates at different follow-up time points (27  3 months).
0.56 
0.86 0.85 0.87 0.86 0.88 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
baseline discharge 3m 6m 12m 27m
ABI ± SD 
P < 0.001 
Figure 8. ABI
Statistically signiﬁcant improvement in ankle-brachial index (ABI) from baseline
to post-procedure maintained at 2 years (27  3 months). m  months; SD Figure 5. Two-Year Primary Patency Stratified by Severe Calcification
Differences in primary patency for severely calciﬁed versus noncalciﬁed lesions
(p  NS). Severe calcium deﬁned as angiographic visual appearance of calciumFigure 6. Two-Year Primary Patency Stratified by Run off Vessel Status
Differences in primary patency on the basis of different number of patent
crural vessels (p  NS). Numbers in left column—1, 2, and 3—refer to the
number of patent crural vessel established  absence of any patent cruralstandard deviation.
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287Discussion
The present report, providing detailed long-term follow-up
on a prospective multicenter registry of PEB for femoropo-
pliteal PTA, has the following implications: 1) primary
patency was favorably maintained in most patients despite a
low stenting rate during the index procedure; 2) accordingly,
a successful repeat revascularization was required in only a
minority of patients (14.3%); and 3) these benefits were
accompanied by similarly favorable results on ankle-brachial
index, ACD, Rutherford class, and quality of life. Never-
theless, it should be recognized that such endpoints were
assessed at fixed time points of 1 and 2 years; hence overall
111 
381 
356 361 
418 
0
100
200
300
400
500
600
baseline 3m 6m 12m 27m
ACD ± SD 
P < 0.001 
Figure 9. ACD
Statistically signiﬁcant improvement in walking distance from baseline to
post-procedure maintained at 2 years (27  3 months). ACD  absolute
claudication distance. m  months; SD  standard deviation.
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
BASELINE 3-MONTH 6
Rutherfo
p < 0.0
Figure 10. Rutherford ClassStatistically signiﬁcant improvement in Rutherford Class (RC) from baseline to post ppatient benefit, besides due to the drug-eluting balloon
effect, might likely have been impacted also by the reported
re-interventions.
Despite ongoing improvements in the endovascular ar-
mamentarium, there is still uncertainty on the most appro-
priate minimally invasive treatment strategy for femoropo-
pliteal artery disease. Despite its established limitations,
standard PTA (balloon-only) is still used by many centers,
especially for simple and short lesions. Self-expandable
bare-metal stents have recently been shown to be beneficial
in comparison with standard PTA, especially when new-
generation devices are used (10,11). Specifically, primary
bare-metal stenting was associated with an 87.3% 12-month
freedom from TLR in comparison with standard balloons in
the RESILIENT trial (Edwards Lifesciences Self-
Expanding Stent Peripheral Vascular Disease Study), which
was largely maintained at 36 months (75.5% vs. 41.8%,
respectively) (11). Similar findings were provided by Schil-
linger et al. (12) after a total of 98 patients for 24 months
after randomization to default bare-metal stent implanta-
tion or standard balloon angioplasty, with TLR in 37.0%
and 53.8%, respectively. However, the inherent theoretical
drawback of such permanent prostheses have not convinced
all operators to use them in routine fashion.
Contrary to the initial findings with everolimus-eluting
devices (13,14), latest results with paclitaxel-eluting stents
seem promising (15,16). In particular, primary paclitaxel-
eluting stenting was associated with an 83.1% primary
patency at 12 months in comparison with standard balloon
H 12-MONTH 27-MONTH
ss shi 
RC 0
RC 1
RC 2
RC 3
RC 4
RC 5
RC 6-MONT
rd Cla
001 rocedure maintained at 2 years (27  3 months).
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288angioplasty in the Zilver PTX randomized trial (15). In-
deed, results of the drug-eluting stent arm of the Zilver
PTX trial seem similar to those hereby achieved.
In contrast to an elective stent strategy, such as drug-
eluting stents, PEBs might best fit a long-term therapy
strategy as needed for claudicant patients. With the un-
avoidable disease progress within and outside the treated
lesion, PEBs represent a viable option that is less likely to
impact future interventions when compared with any first-
line stent strategy.
PEBs have been proposed in the last few years as a novel
technology for femoropopliteal PTA, given their favorable
risk-benefit balance in the available randomized trials and
the theoretical advantage of a treatment that does not
require any implantation of permanent prostheses (4,5).
Long-term results on the PaccoCath PEBs have also been
reported (4,5); however, these studies were primarily de-
signed upon a 6-month angiographic primary endpoint and
did not provide functional assessment.
To expand the assessment of PEBs beyond the bound-
aries typical of proof-of-concept randomized trials, we have
designed a multicenter prospective registry of PEBs for
femoropopliteal revascularization and built upon a primary
patency primary endpoint and various functional secondary
endpoints. Clinical results up to 12 months have been
reported in detail elsewhere (7), but given the lack of
carefully collected long-term data on such a clinical topic,
clinical follow-up was prolonged to 24 months, including
adjudication of adverse events as well as appraisal of key
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Mobility Self-Care
% of paents with some and se
BASELINE 3-MONTH FUP 6-M
P < 0.001 
P = 0.309 
° 
Figure 11. Quality of Life
Statistically signiﬁcant improvement (°) in quality of life appraised by EuroQol
(27  3 months). FUP  follow-up.quantitative and objective estimates pertinent to patientswith claudication and rest-pain, such as primary patency,
ankle-brachial index, ACD, and quality of life measure-
ments. We continued to focus on primary patency as
primary endpoint, because this can best appraise the results
after revascularization, as indeed other endpoints (such as
TLR rate) might suggest more optimistic results for a given
revascularization technique.
We found that PEBs were associated with favorable
results at more than 2 years after the index procedure.
Although some attrition between 1 and 2 years in primary
patency, TLR rates, Rutherford class, and quality of life was
evident, this should come as no surprise in light of the
natural course of the disease, which typically progresses
beyond the target lesion. Conversely, the favorable trends in
ankle-brachial index and ACD, which showed an overall
increase during such time (from 0.86 to 0.88 and from 361
to 418, respectively), support the favorable risk-benefit
balance of PEBs in this clinical setting. Finally, no evidence
of late catch-up phenomenon was found, despite a dual
antiplatelet therapy limited by protocol to 12 weeks (unless
bail-out stenting occurred). Results on subgroups (stented
vs. not stented, calcified vs. not calcified, popliteal involve-
ment vs. no involvement, occlusion vs. stenoses) are inter-
esting but, due the small number, should not be considered
conclusive.
Study limitations. Limitations of this work include the
nonrandomized design, the focus on a single treatment
strategy, and the focus on patients without severe critical
limb ischemia with femoropopliteal lesions up to 15 cm.
vies Pain/Discomfort Anxiety/Depression
 problem detected by EQoL 5D 
P 12-MONTH FUP 27-MONTH FUP
001 
P < 0.001 
P = 0.497 
° ° 
5D from baseline to post-procedure maintained at 2 yearsUsual ac
rious
ONTH FU
P < 0.
(EQol)However, these features might offer clear and unconfounded
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289insights on the long-term clinical outlook of patients with
femoropopliteal artery disease and Rutherford class 2 to 4
presentation treated with PEBs. Further insights on the
risk-benefit balance of these devices will necessarily require
careful analysis of recent or ongoing randomized clinical
trials, comparing them with standard balloon-only PTA
and routine stenting.
Conclusions
PEBs are associated with favorable long-term clinical out-
comes in patients with femoropopliteal artery disease re-
quiring percutaneous revascularization. These findings sig-
nal that a stent-less therapy approach with IN.PACT
Admiral PEB and optimal PTA provides favorable out-
comes and is likely to leave more interventional options
open for the future.
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